Investigational Drug Information for SCY-078
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug SCY-078?
SCY-078 is an investigational drug.
There have been 15 clinical trials for SCY-078.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 15th 2017.
The most common disease conditions in clinical trials are Candidiasis, Candidiasis, Vulvovaginal, and Candidiasis, Invasive. The leading clinical trial sponsors are Scynexis, Inc., Clinical Network Services (CNS) Pty Ltd, and Inncelerex.
There are four US patents protecting this investigational drug and eighteen international patents.
Summary for SCY-078
| US Patents | 4 |
| International Patents | 18 |
| US Patent Applications | 9 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 3 (2017-11-15) |
| Vendors | 3 |
Recent Clinical Trials for SCY-078
| Title | Sponsor | Phase |
|---|---|---|
| A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole | Scynexis, Inc. | Phase 3 |
| ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects | Inncelerex | Phase 1 |
| ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects | Scynexis, Inc. | Phase 1 |
Clinical Trial Summary for SCY-078
Top disease conditions for SCY-078
Top clinical trial sponsors for SCY-078
US Patents for SCY-078
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SCY-078 | See Plans and Pricing | Salts and polymorphs of SCY-078 | SCYNEXIS, INC. (Research Triangle Park, NC) | See Plans and Pricing |
| SCY-078 | See Plans and Pricing | Salts and polymorphs of SCY-078 | SCYNEXIS, INC. (Jersey City, NJ) | See Plans and Pricing |
| SCY-078 | See Plans and Pricing | Salts and polymorphs of SCY-078 | SCYNEXIS, INC. (Jersey City, NJ) | See Plans and Pricing |
| SCY-078 | See Plans and Pricing | Antifungal agents | Merck Sharp & Dohme Corp. (Rahway, NC) Seynexis, Inc. (Research Triangle Park, NC) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SCY-078
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SCY-078 | Denmark | DK3247711 | 2035-01-19 | See Plans and Pricing |
| SCY-078 | Eurasian Patent Organization | EA036874 | 2035-01-19 | See Plans and Pricing |
| SCY-078 | Eurasian Patent Organization | EA201791645 | 2035-01-19 | See Plans and Pricing |
| SCY-078 | European Patent Office | EP3247711 | 2035-01-19 | See Plans and Pricing |
| SCY-078 | Spain | ES2913111 | 2035-01-19 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
